Proficio Capital Partners LLC Has $596,000 Stake in Stryker Co. (NYSE:SYK)

Proficio Capital Partners LLC raised its stake in shares of Stryker Co. (NYSE:SYK) by 46.2% in the fourth quarter, Holdings Channel.com reports. The firm owned 1,656 shares of the medical technology company’s stock after buying an additional 523 shares during the period. Proficio Capital Partners LLC’s holdings in Stryker were worth $596,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of SYK. RTW Investments LP bought a new stake in shares of Stryker in the 3rd quarter worth approximately $143,392,000. State Street Corp raised its holdings in Stryker by 2.2% during the 3rd quarter. State Street Corp now owns 14,582,959 shares of the medical technology company’s stock valued at $5,279,788,000 after acquiring an additional 316,404 shares during the period. FMR LLC raised its holdings in Stryker by 3.0% during the 3rd quarter. FMR LLC now owns 7,306,994 shares of the medical technology company’s stock valued at $2,639,725,000 after acquiring an additional 215,782 shares during the period. Public Sector Pension Investment Board grew its position in shares of Stryker by 1,552.7% during the 3rd quarter. Public Sector Pension Investment Board now owns 207,889 shares of the medical technology company’s stock valued at $75,102,000 after purchasing an additional 195,310 shares in the last quarter. Finally, Alecta Tjanstepension Omsesidigt purchased a new position in shares of Stryker during the 4th quarter valued at $63,556,000. Institutional investors own 77.09% of the company’s stock.

Insiders Place Their Bets

In other news, Director Allan C. Golston sold 2,458 shares of the firm’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the sale, the director now directly owns 14,895 shares in the company, valued at $5,705,827.65. This trade represents a 14.16 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Ronda E. Stryker sold 201,392 shares of the firm’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the sale, the director now owns 3,642,075 shares in the company, valued at $1,428,567,498. The trade was a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 5.90% of the company’s stock.

Stryker Trading Down 0.8 %

NYSE:SYK opened at $371.38 on Monday. The company’s 50 day moving average price is $384.28 and its 200-day moving average price is $374.12. Stryker Co. has a 52 week low of $314.93 and a 52 week high of $406.19. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. The stock has a market cap of $141.71 billion, a price-to-earnings ratio of 47.86, a PEG ratio of 2.93 and a beta of 0.95.

Stryker (NYSE:SYK) last issued its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period in the previous year, the company earned $3.46 EPS. On average, equities research analysts forecast that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a $0.84 dividend. The ex-dividend date is Monday, March 31st. This represents a $3.36 annualized dividend and a yield of 0.90%. Stryker’s payout ratio is presently 43.30%.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. The Goldman Sachs Group set a $422.00 target price on shares of Stryker in a research report on Tuesday, March 4th. JPMorgan Chase & Co. upped their price target on shares of Stryker from $420.00 to $445.00 and gave the company an “overweight” rating in a research report on Wednesday, January 29th. Royal Bank of Canada upped their price objective on shares of Stryker from $425.00 to $435.00 and gave the company an “outperform” rating in a research note on Wednesday, January 29th. StockNews.com downgraded shares of Stryker from a “buy” rating to a “hold” rating in a research note on Thursday, March 6th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $442.00 price target on shares of Stryker in a research note on Friday. Five equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat, Stryker has an average rating of “Moderate Buy” and a consensus price target of $421.90.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.